quinoxalines has been researched along with Movement Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fröhlich, K; Schäfer, F; Schmidt, W; Striggow, F; Striggow, V | 1 |
| Dai, W; Deng, W; Follett, PL; Jensen, FE; Massillon, LJ; Rosenberg, PA; Talos, DM; Volpe, JJ | 1 |
2 other study(ies) available for quinoxalines and Movement Disorders
| Article | Year |
|---|---|
Cannabinoid receptor subtypes 1 and 2 mediate long-lasting neuroprotection and improve motor behavior deficits after transient focal cerebral ischemia.
Topics: Animals; Arachidonic Acids; Brain; Brain Infarction; Cannabinoids; Disease Models, Animal; Dose-Response Relationship, Drug; Ectodysplasins; Endocannabinoids; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Indans; Infarction, Middle Cerebral Artery; Leukocyte Common Antigens; Male; Movement Disorders; Neuroprotective Agents; Polyunsaturated Alkamides; Psychomotor Performance; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Sulfonic Acids; Time Factors | 2012 |
Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: a protective role for topiramate.
Topics: Animals; Calcium; Cell Death; Cell Differentiation; Cell Division; Disease Models, Animal; Dose-Response Relationship, Drug; Erythroid Precursor Cells; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Fructose; Gestational Age; Humans; Hypoxia-Ischemia, Brain; Infant, Newborn; Kainic Acid; Leukomalacia, Periventricular; Movement Disorders; Neuroprotective Agents; Oligodendroglia; Quinoxalines; Rats; Receptors, AMPA; Receptors, Glutamate; Topiramate; Treatment Outcome | 2004 |